Lantheus Holdings, parent company of Lantheus Medical Imaging, has completed its purchase of oncology drug developer Progenics Pharmaceuticals.
The deal was first announced in October of last year. Under the purchase terms, Progenics stockholders have received 0.31 share of Lantheus stock for each share of Progenics stock. They also received nontradeable contingent value right that is payable on completion of milestones related to the financial performance of PyLTM, Progenics' prostate-specific imaging agent.
Progenics will be delisted from Nasdaq, Lantheus said.
